Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor
Completed · Phase 3
Conditions studied: Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
In brief
This phase III trial is studying how well combination chemotherapy followed by second-look surgery and radiation therapy works in treating children with nonmetastatic medulloblastoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with surgery and radiation therapy may kill more tumor cells.
Key facts
- Study ID
- NCT00006461
- Run by
- Children's Oncology Group
- People needed
- 82
- Starts
- 2000-10-01
- Last updated by the study team
- 2013-08-09
Who can join
Age: any, up to 3. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed primary medulloblastoma or posterior fossa primitive neuroectodermal tumor
- Prior definitive tumor resection within 6 weeks of study
- No evidence of metastases
- Hemoglobin at least 10 g/dL
- Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
- AST less than 2.5 times normal
- Bilirubin less than 1.5 mg/dL
- Creatinine less than 1.2 mg/dL
- Creatinine clearance greater than 70 mL/min
- No prior chemotherapy
- No prior radiotherapy
- See Disease Characteristics
Where it is running
- Children's Oncology Group — Arcadia, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.